Omeprazol Richter (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Richter, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Richter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Richter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Richter is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSA‑related gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Acute interstitial nephritis: kidney inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic injury: elevated liver enzymes. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term use.

Before starting Omeprazol Richter, consider the following safety points: - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: assess need for continued therapy after 12 months. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: markedly decreased absorption. - Methotrexate (high dose): increased systemic exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, require more frequent monitoring. - Digoxin: modest increase in serum levels. - Phenytoin: decreased plasma concentration. - Diazepam: increased sedation risk. - Iron supplements: reduced absorption, separate dosing by at least 2 h.